Prospects for Targeting PD-1 and PD-L1 in Various Tumor Types

被引：0

作者：

Kim, Joseph W. ^{[1
]}

Eder, Joseph Paul ^{[1
]}

机构：

[1] Yale Univ, Sch Med, Yale Comprehens Canc Ctr, Dept Med, New Haven, CT 06520 USA

来源：

ONCOLOGY-NEW YORK | 2014年 / 28卷

关键词：

RENAL-CELL CARCINOMA; CANCER; SAFETY; MELANOMA; SURVIVAL; ANTIBODY; IPILIMUMAB; ANTI-PD-1; EXPRESSION; REGRESSION;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoints, such as programmed death ligand 1 (PD-L1) or its receptor, programmed death 1 (PD-1), appear to be Achilles' heels for multiple tumor types. PD-L1 not only provides immune escape for tumor cells but also turns on the apoptosis switch on activated T cells. Therapies that block this interaction have demonstrated promising clinical activity in several tumor types. In this review, we will discuss the current status of several anti-PD-1 and anti-PD-L1 antibodies in clinical development and their direction for the future.

引用

页码：15 / 28

页数：14

共 50 条

[31] Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers
Prodeus, Aaron
Gariepy, Jean
CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
[32] In search of a target: PD-1 and PD-L1 profiling across glioma types
Berghoff, Anna S.
Preusser, Matthias
NEURO-ONCOLOGY, 2016, 18 (10) : 1331 - 1332
[33] Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Wu, Qian
Jiang, Li
Li, Si-cheng
He, Qiao-jun
Yang, Bo
Cao, Ji
ACTA PHARMACOLOGICA SINICA, 2021, 42 (01) : 1 - 9
[34] Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Qian Wu
Li Jiang
Si-cheng Li
Qiao-jun He
Bo Yang
Ji Cao
Acta Pharmacologica Sinica, 2021, 42 : 1 - 9
[35] Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
Rosenblatt, Jacalyn
Avigan, David
BLOOD, 2017, 129 (03) : 275 - 279
[36] Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology
Tran, Tuan Hiep
Tran, Thi Thu Phuong
ROYAL SOCIETY OPEN SCIENCE, 2022, 9 (04):
[37] Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
Annika De Sousa Linhares
Claire Battin
Sabrina Jutz
Judith Leitner
Christine Hafner
Joshua Tobias
Ursula Wiedermann
Michael Kundi
Gerhard J. Zlabinger
Katharina Grabmeier-Pfistershammer
Peter Steinberger
Scientific Reports, 9
[38] Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
Linhares, Annika De Sousa
Battin, Claire
Jutz, Sabrina
Leitner, Judith
Hafner, Christine
Tobias, Joshua
Wiedermann, Ursula
Kundi, Michael
Zlabinger, Gerhard J.
Grabmeier-Pfistershammer, Katharina
Steinberger, Peter
SCIENTIFIC REPORTS, 2019, 9 (1)
[39] Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1
Patera, Andriani C.
Drewry, Anne M.
Chang, Katherine
Beiter, Evan R.
Osborne, Dale
Hotchkiss, Richard S.
JOURNAL OF LEUKOCYTE BIOLOGY, 2016, 100 (06) : 1239 - 1254
[40] Tumor-derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer
Wu, Yunjiao
Fu, Huichao
Hao, Jingwei
Yang, Zhaoyang
Qiao, Xinyi
Li, Yingjie
Zhao, Rui
Lin, Tie
Wang, Yicun
Wang, Meng
FRONTIERS IN IMMUNOLOGY, 2024, 15

← 1 2 3 4 5 →